FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2510143637> ?p ?o ?g. }

• W2510143637 endingPage "2089" @default.
• W2510143637 startingPage "2082" @default.
• W2510143637 abstract "The RAISE phase III clinical trial demonstrated that ramucirumab + FOLFIRI improved overall survival (OS) [hazard ratio (HR) = 0.844, P = 0.0219] and progression-free survival (PFS) (HR = 0.793, P < 0.0005) compared with placebo + FOLFIRI for second-line metastatic colorectal carcinoma (mCRC) patients previously treated with first-line bevacizumab, oxaliplatin, and a fluoropyrimidine. Since some patient or disease characteristics could be associated with differential efficacy or safety, prespecified subgroup analyses were undertaken. This report focuses on three of the most relevant ones: KRAS status (wild-type versus mutant), age (<65 versus ≥65 years), and time to progression (TTP) on first-line therapy (<6 versus ≥6 months).OS and PFS were evaluated by the Kaplan-Meier analysis, with HR determined by the Cox proportional hazards model. Treatment-by-subgroup interaction was tested to determine whether treatment effect was consistent between subgroup pairs.Patients with both wild-type and mutant KRAS benefited from ramucirumab + FOLFIRI treatment over placebo + FOLFIRI (interaction P = 0.526); although numerically, wild-type KRAS patients benefited more (wild-type KRAS: median OS = 14.4 versus 11.9 months, HR = 0.82, P = 0.049; mutant KRAS: median OS = 12.7 versus 11.3 months, HR = 0.89, P = 0.263). Patients with both longer and shorter first-line TTP benefited from ramucirumab (interaction P = 0.9434), although TTP <6 months was associated with poorer OS (TTP ≥6 months: median OS = 14.3 versus 12.5 months, HR = 0.86, P = 0.061; TTP <6 months: median OS = 10.4 versus 8.0 months, HR = 0.86, P = 0.276). The subgroups of patients ≥65 versus <65 years also derived a similar ramucirumab survival benefit (interaction P = 0.9521) (≥65 years: median OS = 13.8 versus 11.7 months, HR = 0.85, P = 0.156; <65 years: median OS = 13.1 versus 11.9 months, HR = 0.86, P = 0.098). The safety profile of ramucirumab + FOLFIRI was similar across subgroups.These analyses revealed similar efficacy and safety among patient subgroups with differing KRAS mutation status, longer or shorter first-line TTP, and age. Ramucirumab is a beneficial addition to second-line FOLFIRI treatment for a wide range of patients with mCRC.ClinicalTrials.gov, NCT01183780." @default.
• W2510143637 created "2016-09-16" @default.
• W2510143637 creator A5001493210 @default.
• W2510143637 creator A5001591653 @default.
• W2510143637 creator A5015190461 @default.
• W2510143637 creator A5020077097 @default.
• W2510143637 creator A5023085446 @default.
• W2510143637 creator A5025931905 @default.
• W2510143637 creator A5029072392 @default.
• W2510143637 creator A5031770911 @default.
• W2510143637 creator A5033985179 @default.
• W2510143637 creator A5036518135 @default.
• W2510143637 creator A5038655401 @default.
• W2510143637 creator A5051613962 @default.
• W2510143637 creator A5052290056 @default.
• W2510143637 creator A5062748030 @default.
• W2510143637 creator A5067038598 @default.
• W2510143637 creator A5082299919 @default.
• W2510143637 creator A5090645179 @default.
• W2510143637 date "2016-11-01" @default.
• W2510143637 modified "2023-10-12" @default.
• W2510143637 title "Subgroup analysis in RAISE: a randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression" @default.
• W2510143637 cites W129166515 @default.
• W2510143637 cites W1979706544 @default.
• W2510143637 cites W1983763042 @default.
• W2510143637 cites W2003157997 @default.
• W2510143637 cites W2011492006 @default.
• W2510143637 cites W2025992190 @default.
• W2510143637 cites W2047993673 @default.
• W2510143637 cites W2069361214 @default.
• W2510143637 cites W2081238655 @default.
• W2510143637 cites W2103789431 @default.
• W2510143637 cites W2115112566 @default.
• W2510143637 cites W2118059295 @default.
• W2510143637 cites W2121847974 @default.
• W2510143637 cites W2153297361 @default.
• W2510143637 cites W2160373161 @default.
• W2510143637 cites W2166112130 @default.
• W2510143637 cites W4211117646 @default.
• W2510143637 doi "https://doi.org/10.1093/annonc/mdw402" @default.
• W2510143637 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5091322" @default.
• W2510143637 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27573561" @default.
• W2510143637 hasPublicationYear "2016" @default.
• W2510143637 type Work @default.
• W2510143637 sameAs 2510143637 @default.
• W2510143637 citedByCount "50" @default.
• W2510143637 countsByYear W25101436372016 @default.
• W2510143637 countsByYear W25101436372017 @default.
• W2510143637 countsByYear W25101436372018 @default.
• W2510143637 countsByYear W25101436372019 @default.
• W2510143637 countsByYear W25101436372020 @default.
• W2510143637 countsByYear W25101436372021 @default.
• W2510143637 countsByYear W25101436372022 @default.
• W2510143637 countsByYear W25101436372023 @default.
• W2510143637 crossrefType "journal-article" @default.
• W2510143637 hasAuthorship W2510143637A5001493210 @default.
• W2510143637 hasAuthorship W2510143637A5001591653 @default.
• W2510143637 hasAuthorship W2510143637A5015190461 @default.
• W2510143637 hasAuthorship W2510143637A5020077097 @default.
• W2510143637 hasAuthorship W2510143637A5023085446 @default.
• W2510143637 hasAuthorship W2510143637A5025931905 @default.
• W2510143637 hasAuthorship W2510143637A5029072392 @default.
• W2510143637 hasAuthorship W2510143637A5031770911 @default.
• W2510143637 hasAuthorship W2510143637A5033985179 @default.
• W2510143637 hasAuthorship W2510143637A5036518135 @default.
• W2510143637 hasAuthorship W2510143637A5038655401 @default.
• W2510143637 hasAuthorship W2510143637A5051613962 @default.
• W2510143637 hasAuthorship W2510143637A5052290056 @default.
• W2510143637 hasAuthorship W2510143637A5062748030 @default.
• W2510143637 hasAuthorship W2510143637A5067038598 @default.
• W2510143637 hasAuthorship W2510143637A5082299919 @default.
• W2510143637 hasAuthorship W2510143637A5090645179 @default.
• W2510143637 hasBestOaLocation W25101436371 @default.
• W2510143637 hasConcept C121608353 @default.
• W2510143637 hasConcept C126322002 @default.
• W2510143637 hasConcept C142724271 @default.
• W2510143637 hasConcept C143998085 @default.
• W2510143637 hasConcept C187960798 @default.
• W2510143637 hasConcept C204787440 @default.
• W2510143637 hasConcept C207103383 @default.
• W2510143637 hasConcept C27081682 @default.
• W2510143637 hasConcept C2776694085 @default.
• W2510143637 hasConcept C2776705615 @default.
• W2510143637 hasConcept C2777802072 @default.
• W2510143637 hasConcept C2779551604 @default.
• W2510143637 hasConcept C2779804826 @default.
• W2510143637 hasConcept C2780259306 @default.
• W2510143637 hasConcept C2780456651 @default.
• W2510143637 hasConcept C2780739268 @default.
• W2510143637 hasConcept C2781187634 @default.
• W2510143637 hasConcept C31760486 @default.
• W2510143637 hasConcept C44249647 @default.
• W2510143637 hasConcept C50382708 @default.
• W2510143637 hasConcept C526805850 @default.
• W2510143637 hasConcept C71924100 @default.
• W2510143637 hasConcept C90924648 @default.
• W2510143637 hasConceptScore W2510143637C121608353 @default.
• W2510143637 hasConceptScore W2510143637C126322002 @default.

• next